1007219-73-9

Basic information

• Product Name: Methyl 1-methylindazole-6-carboxylate
• Synonyms: Methyl 1-methylindazole-6-carboxylate;methyl 1-methyl-1H-indazole-6-carboxylate;ethyl 2-(1-methyl-1H-indazol-6-yl)acetate;6-(Methoxycarbonyl)-1-methyl-1H-indazole;Methyl 1-Methyl-1H-indazol-6-carboxylate;1-Methyl-1H-indazol-6-carboxylic acid Methyl ester;1-Methyl-1H-indazole-6-carboxylic acid methyl ester
• CAS NO: 1007219-73-9
• Molecular Formula: C10H10N2O2
• Molecular Weight: 190.1986
• Mol File: 1007219-73-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 313.086 °C at 760 mmHg
• Flash Point: 143.149 °C
• Appearance: /
• Density: 1.23±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 1-methylindazole-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1-methylindazole-6-carboxylate(1007219-73-9)
• EPA Substance Registry System: Methyl 1-methylindazole-6-carboxylate(1007219-73-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1007219-73-9(Hazardous Substances Data)

Usage

Uses

1-Methyl-1H-indazole-6-carboxylic Acid Methyl Ester is a useful synthetic intermediate. It is an analog of Indazole-3-carboxylic Acid Methyl Ester (I505250) which has potential as application of N-benzoylindazole derivatives and analogues as inhibitors of human neutrophil elastase. Indazole-3-carboxylic Acid Methyl Ester (I505250) is also used in the preparation of indazole-pyridine based protain kinase/Akt inhibitors.

Upstream product

• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 67-56-1 methanol 
• 590417-94-0 6-bromo-1-methyl-1H-indazole 
• 201230-82-2 carbon monoxide 
• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 1031417-77-2 1-methyl-1H-indazole-6-carboxylic acid 

Relevant articles and documents

Synthetic method 1 - methyl - 111H-indazole -6 - formic acid (by machine translation)

The invention provides a synthetic method, 1 - methyl - 111H-indazole -6 - formic acid. The synthesis method comprises 2 - fluorine -4 - bromobenzaldehyde and methylhydrazine as a raw material, and after the cyclization reaction is carried out 6 - bromo -1 - methyl indazole, then formate esterification reaction and hydrolysis reaction, and the 1 - methyl - 111H (indazole -6 - formic acid; isomers, and the like 1 are avoided, and the problem that impurities are difficult to remove in follow-up separation is avoided. Not only is the product purity, the yield of ring-forming 85% reaction can also reach the unitunits ?, the yield is higher, the product is suitable for small-scale preparation in laboratories, production, reaction conditions are easy to operate, control, production cost, and large-scale industrial production are facilitated. (by machine translation)

ORNITHINE DERIVATIVE

Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.